
FDA grants priority review to tinlarebant NDA for Stargardt disease type 1
Published: | Updated:
FDA grants priority review to Belite Bio's tinlarebant NDA for Stargardt disease type 1, setting a February 2027 PDUFA date for a potential first STGD1 therapy.

